Synthesis of new 1-[N-(4-aminophenyl)-sulfonamide]-thiocabamoyl-Pyrazolines and evaluation of Anti-cholinesterase activity
Alzheimer's disease; Acetylcholinesterase; Butyrylcholinesterase; Sulfonamide; Pyrazoline.
Alzheimer's Disease (DA) is one of the most common dementias in individuals over 65 years of age. It is a progressive illness that affects the thought, memory, learning and language leading the elderly to dependence on their relatives due to the inability to perform activities in their everyday life. One of the main pathological mechanisms responsible for DA is the intense synaptic degeneration where the neurotransmitter acetylcholine (ACh) suffers hydrolysis in presence of cholinesterase’s enzymes, in particular acetylcholinesterase (AChE). Maintaining the proper functioning of synapses in the central and peripheral nervous system is related to inhibition of these enzymes. Previous researches showed compounds derived from Pyrazoline or Sulfonamide as promising enzyme inhibitors. Therefore, this project aims to hybridize the groups Pyrazoline and Sulfonamide in 20 unpublished compounds for subsequent evaluation of the inhibition capacity of the enzymes AChE and BuChE, involved in synaptic degeneration.